82 related articles for article (PubMed ID: 24616766)
1. Successful medical management of a pituitary macroadenoma with features of resistant acromegaly and hyperprolactinemia using pasireotide.
Baagar KA; Sadiq A; Khan AA; Dabbous Z; Rohani Z
Qatar Med J; 2024; 2024(1):17. PubMed ID: 38654814
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly with no pituitary adenoma and no evidence of ectopic source.
Khandelwal D; Khadgawat R; Mukund A; Suri A
Indian J Endocrinol Metab; 2011 Sep; 15 Suppl 3(Suppl3):S250-2. PubMed ID: 22029034
[TBL] [Abstract][Full Text] [Related]
4. Management of persistent acromegaly following primary therapy: The current landscape in the UK.
Kyriakakis N; Seejore K; Hanafy A; Murray RD
Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00158. PubMed ID: 32704572
[TBL] [Abstract][Full Text] [Related]
5. Low libido despite high normal testosterone levels in a male with an FSH-secreting pituitary macroadenoma.
Ghazal Asswad R; Khan MI; Elizabeth Gilkes C; Daousi C; Thondam SK
Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38520752
[TBL] [Abstract][Full Text] [Related]
6. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.
Pirchio R; Auriemma RS; Vergura A; Pivonello R; Colao A
J Endocrinol Invest; 2024 Mar; ():. PubMed ID: 38532073
[TBL] [Abstract][Full Text] [Related]
7. Loss of Efficacy of Pasireotide After its Re-Administration: is There a Reason Why?
Mandanas S; Mathiopoulou L; Boudina M; Chrisoulidou A; Pazaitou-Panayiotou K
Rare Tumors; 2016 Nov; 8(4):6489. PubMed ID: 28191290
[TBL] [Abstract][Full Text] [Related]
8. Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly.
Hayes AG; Penny MJ; Aivazian K; Greenfield JR
JCEM Case Rep; 2024 May; 2(5):luae071. PubMed ID: 38770226
[TBL] [Abstract][Full Text] [Related]
9. Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences.
Chiloiro S; Appetecchia M; Bianchi A; Costa D; De Acetis C; Gargiulo P; Giampietro A; Isidori AM; Jaffrain-Rea ML; Passeri M; Pigliaru F; Poggi M; De Marinis L
Drugs Context; 2024; 13():. PubMed ID: 38817802
[TBL] [Abstract][Full Text] [Related]
10. Predictors of biochemical response to somatostatin receptor ligands in acromegaly.
Marazuela M; Martínez-Hernandez R; Marques-Pamies M; Biagetti B; Araujo-Castro M; Puig-Domingo M
Best Pract Res Clin Endocrinol Metab; 2024 Mar; ():101893. PubMed ID: 38575404
[TBL] [Abstract][Full Text] [Related]
11. Correlation Between Pituitary Adenoma Surgery and Anxiety Disorder: Systematic Review and Meta-Analysis.
Sabahi M; Yousefi O; Kehoe L; Sasannia S; Gerndt C; Adada B; Borghei-Razavi H; Shahlaie K; Palmisciano P
World Neurosurg; 2024 Apr; ():. PubMed ID: 38697260
[TBL] [Abstract][Full Text] [Related]
12. Cervicogenic-Like Headache as the First Symptom of Acromegaly.
Rossetti A; Orge C; Melo V; Melo A
Cureus; 2024 May; 16(5):e60599. PubMed ID: 38894775
[TBL] [Abstract][Full Text] [Related]
13. Pituitary Macroadenoma: A Comprehensive Case Study of Surgical Intervention and Postoperative Management.
Shah D; Sen J
Cureus; 2024 Apr; 16(4):e59387. PubMed ID: 38817533
[TBL] [Abstract][Full Text] [Related]
14. Plurihormonal pituitary adenoma cosecreting ACTH and GH: a rare cause of Cushing's disease.
Amir J; Guiot MC; Garfield N
BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36410786
[TBL] [Abstract][Full Text] [Related]
15. Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly.
Fukunaga K; Imachi H; Sato S; Kobayashi T; Yoshioka Y; Saheki T; Ban N; Urushihara K; Lyu J; Dong T; Ishikawa R; Kadota K; Haba R; Inoshita N; Murao K
Intern Med; 2021 Apr; 60(7):1047-1053. PubMed ID: 33162471
[TBL] [Abstract][Full Text] [Related]
16. How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?
Torregrosa-Quesada ME; García-Martínez A; Silva-Ortega S; Martínez-López S; Cámara R; Fajardo C; Lamas C; Aranda I; Picó A
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31835737
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors.
Greenman Y; Stern N
Pituitary; 2016 Dec; 19(6):605-611. PubMed ID: 27639583
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma.
Rajendran R; Naik S; Sandeman DD; Nasruddin AB
Endocrinol Diabetes Metab Case Rep; 2013; 2013():130026. PubMed ID: 24616766
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
